MX2017016491A - Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). - Google Patents

Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).

Info

Publication number
MX2017016491A
MX2017016491A MX2017016491A MX2017016491A MX2017016491A MX 2017016491 A MX2017016491 A MX 2017016491A MX 2017016491 A MX2017016491 A MX 2017016491A MX 2017016491 A MX2017016491 A MX 2017016491A MX 2017016491 A MX2017016491 A MX 2017016491A
Authority
MX
Mexico
Prior art keywords
methods
mtor inhibitor
hematological malignancy
combination therapy
inhibitor combination
Prior art date
Application number
MX2017016491A
Other languages
English (en)
Inventor
ALLES Mark
P Desai Neil
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2017016491A publication Critical patent/MX2017016491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención tiene relación con métodos y composiciones para el tratamiento de una malignidad hematológica administrando composiciones que comprenden nanopartículas que comprenden un inhibidor de mTOR (como una droga limus, por ejemplo, sirolimus o un derivado del mismo) y una albúmina en combinación con composiciones que comprenden un segundo agente terapéutico.
MX2017016491A 2015-06-29 2016-06-29 Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor). MX2017016491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186320P 2015-06-29 2015-06-29
PCT/US2016/040201 WO2017004266A1 (en) 2015-06-29 2016-06-29 Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy

Publications (1)

Publication Number Publication Date
MX2017016491A true MX2017016491A (es) 2018-08-16

Family

ID=57609070

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016491A MX2017016491A (es) 2015-06-29 2016-06-29 Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).

Country Status (15)

Country Link
US (3) US20180256551A1 (es)
EP (1) EP3313409A4 (es)
JP (1) JP2018526334A (es)
KR (1) KR20180019231A (es)
CN (1) CN107921050A (es)
AU (1) AU2016287507B8 (es)
BR (1) BR112017028132A2 (es)
CA (1) CA2990705A1 (es)
CL (1) CL2017003458A1 (es)
EA (1) EA201890159A1 (es)
HK (1) HK1247092A1 (es)
IL (1) IL256378B2 (es)
MX (1) MX2017016491A (es)
WO (1) WO2017004266A1 (es)
ZA (1) ZA201800366B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2117520T (pt) 2006-12-14 2018-12-04 Abraxis Bioscience Llc Terapia do cancro da mama com base no estado do receptor do hormona com nanoparticulas compreendendo taxane
WO2011123393A1 (en) 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
BR112013027674A2 (pt) 2011-04-28 2016-09-06 Abraxis Bioscience Llc "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
PT2790675T (pt) 2011-12-14 2019-09-23 Abraxis Bioscience Llc Utilização de excipientes poliméricos para a liofilização ou a congelação de partículas
ES2804323T3 (es) 2013-03-12 2021-02-05 Abraxis Bioscience Llc Procedimientos de tratamiento de cáncer de pulmón
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
EP3313401B1 (en) 2015-06-29 2021-10-06 Abraxis BioScience, LLC Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
US20190270733A1 (en) * 2018-03-01 2019-09-05 Reaction Biology Corp. Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof
WO2019169257A1 (en) 2018-03-01 2019-09-06 Reaction Biology Corp. Histone deacetylase inhibitors and methods of use thereof
IL277402B1 (en) 2018-03-20 2026-04-01 Abraxis Bioscience Llc Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin
SG11202011462SA (en) * 2018-05-22 2020-12-30 Abraxis Bioscience Llc Methods and compositions for treating pulmonary hypertension
US12239636B2 (en) 2018-09-26 2025-03-04 The Feinstein Institutes For Medical Research Combined sirolimus and nintedanib therapy for vascular lesions and hereditary hemorrhagic telangiectasia
EP3941551A4 (en) * 2019-03-19 2023-01-18 Abraxis BioScience, LLC SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES WITH AN MTOR INHIBITOR AND ALBUMIN FOR THE TREATMENT OF DISEASES
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
WO2020194243A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with lenalidomide and dexamethasone
KR20220106758A (ko) 2019-10-28 2022-07-29 아브락시스 바이오사이언스, 엘엘씨 알부민 및 라파마이신의 제약 조성물
EP4139358A1 (en) * 2020-04-20 2023-03-01 Jounce Therapeutics, Inc. Compositions and methods for vaccination and the treatment of infectious diseases
US20230381309A1 (en) * 2020-10-13 2023-11-30 Immunovaccine Technologies Inc. Methods of treating diffuse large b-cell lymphoma
CN112562867A (zh) * 2021-02-22 2021-03-26 天津迈德新医药科技有限公司 一种预测极早期hiv感染风险的装置、存储介质和电子装置
CN117045800A (zh) * 2022-05-06 2023-11-14 上海科技大学 mTOR抑制剂增强靶向蛋白降解药物功效的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1585548B1 (en) * 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
CN101730526A (zh) * 2007-03-07 2010-06-09 阿布拉科斯生物科学有限公司 作为抗癌剂的包含雷帕霉素和白蛋白的纳米颗粒
LT2481402T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelė, apimanti rapamiciną ir albuminą, kaip priešvėžinį agentą
WO2009024531A1 (en) * 2007-08-17 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for treating and diagnosing hematologic malignancies
WO2010083298A1 (en) * 2009-01-14 2010-07-22 Health Research Inc. Methods and compositions containing mtor inhibitors for enhancing immune responses
CA2903548A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
EP2986318A1 (en) * 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer

Also Published As

Publication number Publication date
JP2018526334A (ja) 2018-09-13
AU2016287507B2 (en) 2021-09-23
CA2990705A1 (en) 2017-01-05
AU2016287507A1 (en) 2018-02-01
IL256378B2 (en) 2023-03-01
EP3313409A1 (en) 2018-05-02
WO2017004266A1 (en) 2017-01-05
EP3313409A4 (en) 2018-12-26
EA201890159A1 (ru) 2018-11-30
KR20180019231A (ko) 2018-02-23
CL2017003458A1 (es) 2018-05-11
US20190175564A1 (en) 2019-06-13
ZA201800366B (en) 2022-04-28
CN107921050A (zh) 2018-04-17
HK1247092A1 (zh) 2018-09-21
US20240082224A1 (en) 2024-03-14
IL256378B (en) 2022-11-01
BR112017028132A2 (pt) 2018-08-28
US20180256551A1 (en) 2018-09-13
IL256378A (en) 2018-02-28
AU2016287507B8 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
HK1247092A1 (zh) 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
NZ738929A (en) Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy
PH12012502380B1 (en) Methods of treatment of pancreatic cancer
MX2015008889A (es) Metodo para tratar cancer con base en el estado de la mutacion k-ras.
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
MX2016007351A (es) Terapia de combinacion para tratar cancer.
NZ700759A (en) Combination therapy for treating cancer
MX2015011783A (es) Metodos para tratar tumores solidos pediatricos.
WO2014194254A9 (en) Treatment of cancers using pi3 kinase isoform modulators
BR112017027954A2 (pt) métodos de tratamento de tumores de célula epitelioide
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2016010134A (es) Composicion farmaceutica que comprende compuesto de diaminocarboxamida heterociclica como ingrediente activo.
MX2019003694A (es) Metodos para tratar cancer del tracto biliar.
MY197664A (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
WO2012158776A3 (en) Combination therapy for treatment of cancer
HK1229709A1 (en) Combination therapy for treating cancer
HK1183815A (en) Methods of treatment of pancreatic cancer
HK1207008A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis